24 completed, 6 terminated, 3 withdrawn. 33 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 24, Terminated 6, Withdrawn 3 |
| Phase 1 | 7 | Completed 6, Terminated 1 |
Follow Recurrent Colon Cancer: new trials by email Literature Review of Recurrent Colon Cancer trials Research Report on Recurrent Colon Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer ziv-aflibercept, leucovorin calcium, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | University of Southern California | 2015-03-01 | 2015-05-06 | |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab panitumumab, irinotecan hydrochloride, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Completed | John Hays | 16 | 2013-02-01 | 2025-02-05 |
| Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer linifanib - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2011-06-01 | 2014-08-26 |
| Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer oxaliplatin, leucovorin calcium, fluorouracil - Liver Metastases, Recurrent Colon Cancer | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2011-03-01 | 2016-07-19 |
| Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-12-01 | 2017-04-04 | |
| RO4929097 in Treating Patients With Metastatic Colorectal Cancer gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2010-05-01 | 2014-05-20 |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer entinostat, azacitidine, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2010-04-01 | 2014-08-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PD-0332991 - Adult Solid Tumor, Adenocarcinoma of the Colon | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 304 | 2009-10-01 | 2021-03-11 |
| Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer sorafenib tosylate, bevacizumab - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 83 | 2009-09-01 | 2026-01-20 |
| Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment fluorouracil, leucovorin calcium, vorinostat - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Completed | Roswell Park Cancer Institute | 58 | 2009-07-01 | 2014-06-23 |
| Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma erlotinib hydrochloride, placebo, laboratory biomarker analysis - Adenomatous Polyp, Recurrent Colon Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2008-07-01 | 2015-01-06 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-10-01 | 2015-03-31 |
| Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer dasatinib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2007-07-01 | 2014-05-19 |
| AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer saracatinib, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2006-11-01 | 2019-08-20 |
| VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer aflibercept - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 75 | 2006-10-01 | 2024-03-04 |
| Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery gemcitabine hydrochloride, floxuridine, proteomic profiling - Liver Metastases, Recurrent Colon Cancer | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 16 | 2005-06-13 | 2026-11-03 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer ispinesib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2005-01-01 | 2015-03-02 |
Showing 20 of 33. Sign in to see all of them.
Colonic Neoplasms (33) · Rectal Neoplasms (32) · Carcinoma, Renal Cell (4) · Breast Neoplasms (3) · Pancreatic Neoplasms (3) · Salivary Gland Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Esthesioneuroblastoma, Olfactory (2) · Laryngeal Neoplasms (2) · Mouth Neoplasms (2) · Nasopharyngeal Neoplasms (2) · Teratoma (2) · Testicular Neoplasms (2)
Colonic Diseases (33) · Digestive System Diseases (33) · Digestive System Neoplasms (33) · Gastrointestinal Diseases (33) · Intestinal Diseases (33) · Intestinal Neoplasms (33) · Neoplasms by Site (33) · Gastrointestinal Neoplasms (32) · Neoplasms (32) · Rectal Diseases (32) · Colorectal Neoplasms (31) · Neoplasms by Histologic Type (7) · Male Urogenital Diseases (6) · Neoplasms, Glandular and Epithelial (6) · Urogenital Diseases (6)
Fluorouracil (8) · Leucovorin (8) · Bevacizumab (6) · Irinotecan (6) · Oxaliplatin (6) · Cetuximab (4) · Erlotinib Hydrochloride (3) · Floxuridine (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Capecitabine (2) · Fluorodeoxyglucose F18 (2) · aflibercept (2) · 2C4 antibody (1) · 4-phenylbutyric acid (1) · Azacitidine (1)
National Cancer Institute (NCI) (20) · City of Hope Medical Center (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Burzynski Research Institute (1) · John Hays (1) · Klus Pharma Inc. (1) · National Institutes of Health Clinical Center (CC) (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Sanjiv Sam Gambhir (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1)
United States (31) · Canada (2)
Jeffrey Wong (2) · Afsaneh Barzi (1) · Alain Mita (1) · Allyson Ocean (1) · Amit Oza (1) · Axel Grothey, MD (1) · Cathy Eng (1) · Edward Martin, MD (1) · H. Richard Alexander, Jr. (1) · Hedy Kindler (1) · James Abbruzzese (1) · Jean-Nicolas Vauthey (1) · John Hays, MD (1) · Jonathan Strosberg (1) · Jordan Berlin, MD (1)
PMID 17634125, PMID 20048179, PMID 21208843, PMID 24583822, PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872, PMID 32201506, PMID 32641862, PMID 32692450
N01CM17003 (2), N01CM62201 (2), N01CM62202 (2), U10CA025224 (2), N01CM00038 (1), N01CM00099 (1), N01CM17101 (1), N01CM17102 (1), N01CM17103 (1), N01CM17105 (1), N01CM17107 (1), N01CM62203 (1), N01CM62204 (1), N01CM62206 (1), N01CM62208 (1)